PTC Therapeutics Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
991
- Stock Symbol
-
PTCT
- Investments
-
8
- Share Price
-
$56.42
- (As of Friday Closing)
PTC Therapeutics General Information
Description
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Contact Information
Website
www.ptcbio.comCorporate Office
- 500 Warren Corporate Center Drive
- Warren, NJ 07059
- United States
Corporate Office
- 500 Warren Corporate Center Drive
- Warren, NJ 07059
- United States
PTC Therapeutics Stock Performance
As of 20-Nov-2026, PTC Therapeutics’s stock price is $56.42. Its current market cap is $4.71B with 83.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $56.42 | $58.33 | $56.18 - $90.87 | $4.71B | 83.5M | 1.07M | -$1.32 |
PTC Therapeutics Financials Summary
As of 30-Sep-2026, PTC Therapeutics has a trailing 12-month revenue of $1.16B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,873,977 | 4,821,009 | 2,868,277 | 2,489,308 |
| Revenue | 1,155,554 | 1,730,655 | 806,780 | 937,822 |
| EBITDA | 174,483 | 887,664 | (120,463) | (330,340) |
| Net Income | (105,971) | 682,644 | (363,295) | (626,604) |
| Total Assets | 3,207,715 | 2,898,767 | 1,705,024 | 1,895,698 |
| Total Debt | 636,034 | 2,707,064 | 2,471,072 | 2,229,123 |
PTC Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PTC Therapeutics Comparisons
Industry
Financing
Details
PTC Therapeutics Competitors (73)
One of PTC Therapeutics’s 73 competitors is Avidity Biosciences, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Avidity Biosciences | Formerly VC-backed | San Diego, CA | ||||
| Travere Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Arcturus Therapeutics Holdings | Formerly VC-backed | San Diego, CA | ||||
| Pfizer 21 | Corporation | Ocean, NJ | ||||
| Rallybio | Formerly VC-backed | New Haven, CT |
PTC Therapeutics Patents
PTC Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260337201-A1 | Process for producing crystalline forms of sepiapterin | Pending | 18-Apr-2025 | ||
| WO-2026221882-A1 | Process for producing crystalline forms of sepiapterin | Pending | 18-Apr-2025 | ||
| US-20260078174-A1 | Single-chain medi1341 antibody-transferrin fusion protein for enhanced efficacy and indications | Pending | 16-Sep-2024 | ||
| US-20260078173-A1 | Single-chain zagotenemab antibody-transferrin fusion protein for enhanced efficacy and indications | Pending | 16-Sep-2024 | ||
| US-20260070968-A1 | Single-chain ustekinumab antibody-transferrin fusion protein for enhanced efficacy and indications | Pending | 11-Sep-2024 | C07K14/79 |
PTC Therapeutics Signals
PTC Therapeutics Investments & Acquisitions (8)
PTC Therapeutics’s most recent deal was a Corporate Asset Purchase with Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) for . The deal was made on 21-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) | 21-Sep-2026 | Corporate Asset Purchase | Buildings and Property | ||
| ONODERA GT Pharma | 31-Oct-2022 | Later Stage VC | Biotechnology | ||
| Censa Pharmaceuticals | 29-May-2020 | Merger/Acquisition | Drug Discovery | ||
| BioElectron Technology (Inflammatory and Central Nervous System Disorders Focussed Assets) | 29-Oct-2019 | Corporate Asset Purchase | Buildings and Property | ||
| BioElectron Technology | 25-Oct-2019 | Merger/Acquisition | Drug Discovery |
PTC Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
27.28 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
PTC Therapeutics FAQs
-
When was PTC Therapeutics founded?
PTC Therapeutics was founded in 1998.
-
Where is PTC Therapeutics headquartered?
PTC Therapeutics is headquartered in Warren, NJ.
-
What is the size of PTC Therapeutics?
PTC Therapeutics has 991 total employees.
-
What industry is PTC Therapeutics in?
PTC Therapeutics’s primary industry is Clinics/Outpatient Services.
-
Is PTC Therapeutics a private or public company?
PTC Therapeutics is a Public company.
-
What is PTC Therapeutics’s stock symbol?
The ticker symbol for PTC Therapeutics is PTCT.
-
What is the current stock price of PTC Therapeutics?
As of 20-Nov-2026 the stock price of PTC Therapeutics is $56.42.
-
What is the current market cap of PTC Therapeutics?
The current market capitalization of PTC Therapeutics is $4.71B.
-
What is PTC Therapeutics’s current revenue?
The trailing twelve month revenue for PTC Therapeutics is $1.16B.
-
Who are PTC Therapeutics’s competitors?
Avidity Biosciences, Travere Therapeutics, Arcturus Therapeutics Holdings, Pfizer 21, and Rallybio are some of the 73 competitors of PTC Therapeutics.
-
What is PTC Therapeutics’s annual earnings per share (EPS)?
PTC Therapeutics’s EPS for 12 months was -$1.32.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process